ANIMATION

Palovarotene MOA

Share this animation:

Fibrodysplasia ossificans progressiva, or FOP, is an extremely rare and debilitating disorder, in which bone tissue gradually replaces soft tissue throughout the body, extending the skeleton and “freezing” patients into position. FOP is an autosomal dominant disorder, and is believed to be caused by a mutation in the ACVR1 gene, which results in constitutively active BMP signaling. Clementia Pharmaceuticals is investigating Palovarotene as a RAR-gamma agonist capable of inhibiting BMP signaling, which may prevent heterotopic ossification and slow the progression of this devastating disease.

Share It:
Contact XVIVO

Client


Palovarotene MOA

XVIVO is in a unique class of crackerjack design companies with honest, capable, supremely talented artists, graphic designers, strategists, and project managers, all of whom are committed to excellence in animation. They understand the unique power of this still evolving art form, its ability to distill otherwise unapproachable biochemical data, and to make it available to the untrained marketing professional, all the while preserving the integrity of the science for the experts who have committed their life’s work to drug discovery and development. Ain’t it easy when you know how to do it?

John Lapolla, Asante Communications, LLC
Share this animation: